1. ¹Department of Pathology, Stanford University, Stanford, CA, USA
2. ²Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada

Correspondence: Dr Robert B West, MD, PhD, Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Room H2110, Stanford, CA 94305, USA. E-mail: rbwest@stanford.edu

Received 8 April 2007; Revised 30 August 2007; Accepted 5 September 2007; Published online 11 January 2008.

Abstract

Giant cell tumor of the bone (GCTOB) is a primary bone tumor that occurs mainly in young adults and is capable of locally aggressive growth. Its histologic appearance can resemble a number of benign and malignant tumors but no useful diagnostic marker is known currently. To identify diagnostic markers for this tumor, global gene expression profiling using cDNA microarray was performed on 6 fresh-frozen GCTOB, 3 aneurysmal bone cysts, 4 fibrous dysplasias and 12 giant cell tumors of tendon sheath/diffuse-type giant cell tumors. Unsupervised hierarchical clustering separated the tumors based on their histopathologic types, and significance analysis of microarray identified several genes including TP73L (encoding the p63 protein) that are significantly highly expressed in GCTOB relative to these other tumors. The diagnostic utility of p63 was subsequently confirmed using anti-p63 antibody on a series of 26 GCTOB, 25 aneurysmal bone cysts, 15 chondroblastomas, 13 giant cell reparative granulomas, 13 chondromyxoid fibromas, 4 brown tumors, 4 fibrous dysplasias, 53 giant cell tumors of tendon sheath/diffuse-type giant cell tumors and 385 additional mesenchymal tumors in tissue microarrays. Strong p63 nuclear staining was present in 18 of 26 (69% ) GCTOB, 3 of 15 (20% ) chondroblastomas and in 1 of 25 (4% ) aneurysmal bone cysts while none of the other tumors commonly considered in the differential diagnosis of GCTOB showed any detectable p63 staining. Strong p63 staining is rare in bone and soft-tissue tumors in general. In contrast to the pattern of p63 staining, the majority of the chondroblastomas (70% ) demonstrated S-100 immunoreactivity while only a minority of the GCTOB (8% ) was immunoreactive for S-100. These findings altogether show that p63 can be used as a diagnostic marker to aid the clinical diagnosis of GCTOB.